Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

Journal of Clinical Psychiatry

Volumn 58, Issue 5, 1997, Pages 205-211

  Tran, Pierre V ^a   Dellva, Mary Anne ^a   Tollefson, Gary D ^a   Beasley Jr , Charles M ^a   Potvin, Janet H ^a   Kiesler, Gerilyn M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIMENHYDRINATE; DIPHENHYDRAMINE; HALOPERIDOL; OLANZAPINE; ORPHENADRINE CITRATE; PROCYCLIDINE; TRIHEXYPHENIDYL;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

EID: 0030965787     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n0505     Document Type: Article

References (34)

1. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: psychosis and anxiety. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:399-430
2. Weiden PJ, Shaw E, Mann JJ. Causes of neuroleptic noncompliance. Psychiatric Annals 1986;16(10):571-575
3. Weiden P, Dixon L, Frances A, et al. Neuroleptic noncompliance in schizophrenia. In: Tamminga C, Schulz SC, eds. Advances in Neuropsychiatry and Psychopharmacology, vol 1, Schizophrenia Research. New York, NY: Raven Press; 1991:285-296
4. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995;10(suppl 3):105-114
5. Annable L, Chouinard G, Ross-Chouinard A, et al. The relationship between neuroleptic-induced parkinsonism and tardive dyskinesia. Biol Psychiatry 1991;29(suppl 11S):210S-226S
6. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985;42:874-878
7. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:102-108
8. Ban TA. Psychopharmacology of Thiothixine. New York, NY: Raven Press; 1978:165-208
9. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
10. Naber D, Holzbach R, Perro C, et al. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992; 160(suppl 17):54-59
11. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989;99(suppl):47-53
12. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14(2):87-96
13. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Current Opinion in Neurology and Neurosurgery 1993;6:602-608
14. Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-551
15. Moore NA, Calligaro DO, Wong TD, et al. The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigational Drugs 1993;2:281-293
16. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and AlO dopamine neurons. Neuropsychopharmacology 1996;14(2):97-104
17. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology, 1997;16:1-7
18. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996;124:148-153
19. Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol 1995;10:239-244
20. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(suppl 212):11-19
21. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
22. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, Md: US Dept of Health, Education, and Welfare; 1976
23. Wolters Ech, Jansen ENH, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-1087
24. Beasley CM Jr, Tollefson GD, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14(2):111-123
25. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167
26. Beasley CM Jr, Hamilton SH, Crawford AM, et al, and The Olanzapine E003 Study Group. Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. In press
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
28. Overall JE, Goriam DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
29. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465
30. US Food and Drug Administration. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 2nd ed. Rockville, Md: US Food and Drug Administration; 1985
31. SAS Institute Inc. SAS/STAT User's Guide, version 6, vol 1 & 2. 4th ed. Cary, NC: SAS Institute; 1990
32. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754-758
33. McEvoy JP, Hogarty G, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739-745
34. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-1729